What is the main business of JR?

The main business activity of JR focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on January 15, 2020.

Where is the headquarters located?

The headquarters is located at: ul. Maksymiliana Dudka 18, 44-213 Rybnik.

Who is on the management board?

The management board consists of: Janusz Krzysztof Kobylec (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

How much revenue was generated?

The company reported a revenue of $120 in 2024, which is a decrease of 99.2% compared to 2023.

No, in 2024 the company reported a net loss of $3,510.

Which cost dominates operating expenses?

The largest operating cost category falls under cost of goods and materials sold. This category amounted to $1,449 in 2024, representing 77% of all operating expenses.

JRsp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Suspended

Registry date

2020-01-15

Share capital

5,000.00 PLN

Registered address

ul. Maksymiliana Dudka 18, 44-213 Rybnik, Poland

Electronic delivery address

AE:PL-34253-39858-VBUGV-25

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 1 of 5 financial statements was filed late (for 2021, 220 days late).

2025not filed
202431/03/2025
202330/04/2024
202228/06/2023
202120/02/2023
202024/09/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue

This companyUSD 119.59MedianUSD 917.74kAverageUSD 25.73m

Net profit

This companyUSD -3.51kMedianUSD 14.44kAverageUSD 2.75m

Operating costs

This companyUSD 1.88kMedianUSD 860.03kAverageUSD 21.34m

Assets

This companyUSD 11.36kMedianUSD 883.09kAverageUSD 31.39m

Industry

Authorized Representatives

Janusz Krzysztof Kobylec – President of the Management Board

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Janusz Krzysztof Kobylecage 50	50	$675.31	50%
Marek Damian Kobylecage 44	50	$675.31	50%

Janusz Krzysztof Kobylec and Marek Damian Kobylec hold a combined 100% – the ownership structure indicates family control.

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2020-03-01.

No bank accounts reported to the VAT Taxpayer Register.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
May 18, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$1,282$1,282	Prezydent Miasta Rybnik

Competitors

Name	Revenue	Website
F1 PharmaS.A.	$272,113.66	f1pharma.pl
Ti-Comsp. z o.o.	$157,549.77	ticomglobal.com
LideoS.A.	$95,067.91	lideo.tech
Munar PharmaS.A.	$85,649.72	munar.pl
BIO Animalisp. z o.o.	$49,176.96	proanimali.com
Ampliconsp. z o.o.	$48,330.99	amplicon.pl
Xenira Pharmaceuticalssp. z o.o.	$26,670.82	xenirapharma.com
Sanford Biotechsp. z o.o.	$2,586.64	sanfordbiotech.com
Cefeasp. z o.o.	$294.66	cefea.pl
Auxilius PharmaS.A.	$0.83	auxiliuspharma.com